$PEPG News
Last published 3h ago
- 3h agoPEPGPepGen Announces Pricing of $125 Million Public OfferingBusiness WireBOSTON--(BUSINESS WIRE)--PepGen Announces Pricing of $125.0 Million Public Offering
- 1d agoPEPGPepGen Announces Proposed $125.0 Million Public Offering of Common StockBusiness WireBOSTON--(BUSINESS WIRE)--PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
- 1d agoPEPGPepGen Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 8.01 Item 9.01
- 1d agoPEPGPepGen Reports Third Quarter 2026 Financial Results and Recent Corporate HighlightsBusiness WireBOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
- 1d agoPEPGPepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional MeasuresBusiness WireBOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results
- 1d agoPEPGTrading halt: PepGen Inc. (PEPG), News pendingNasdaq Trading HaltsHalted 2026-11-10 06:56:00.000 ET, resumption quote none, resumption trade none.
- 3mo agoPEPGPepGen Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsBusiness Wire– DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg – – 10 mg/kg FREEDOM2-DM1 cohort fully enrolled,
- 3mo agoPEPGPepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB ReviewBusiness Wire– DSMB also recommended dose escalation in FREEDOM-OLE from 5 mg/kg to 10 mg/kg – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the
- 4mo agoKLRSPEPGIMRXKalaris Appoints Laurie Keating to Board of DirectorsGlobeNewswireBERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
- 5mo agoPEPGPepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 ProgramBusiness WirePepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases,
- 6mo agoPEPGPepGen Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsBusiness Wire– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort – – The FREEDOM2 10 mg/kg cohort is fully
- 7mo agoPEPGPEPGEN WEBCAST - PEPGEN INCEarnings Call TranscriptsWelcome to the PEPGEN conference call to discuss top-line results from Lois Dose, MAD cohort, in the Phase 2, Freedom 2 study, demonstrating promising safety, splicing, and VHOT data. At this time, all participants are i
- 7mo agoPEPGPepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT DataBusiness Wire– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of 7.3% observed with PGN-EDODM1 (n=6) versus 6.8% with placebo
- 8mo agoPEPGPepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate HighlightsBusiness Wire– FREEDOM2-DM1 5 mg/kg cohort data expected in Q1 2026 – – Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected in 2H 2026 – – FREEDOM2 trial open in South Korea,
- 8mo agoPEPGPepGen Announces Regulatory Updates on FREEDOM2Business Wire- U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and New Zealand and dosing
- 8mo agoPEPGPepGen to Participate in the Leerink Global Healthcare ConferenceBusiness WirePepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases,
- 11mo agoPEPGPepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal OfficerBusiness WirePepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases,
- 11mo agoPEPGPepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal OfficerBusiness WirePepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases,
- 12mo agoPEPGPepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 MoleculeBusiness WireComposition of matter patent covers the Company's novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the
- 12mo agoPEPGPepGen Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsBusiness Wire– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients enrolled and having
- 1y agoPEPGPepGen to Participate in Upcoming Investor ConferencesBusiness WirePepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases,
- 1y agoPEPGPepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle SocietyBusiness WirePepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases,
- 1y agoPEPGPepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesBusiness WirePepGen Inc.
- 1y agoPEPGPepGen Announces Pricing of $100 Million Public OfferingBusiness WirePepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological
- 1y agoPEPGPepGen Announces Proposed Public OfferingBusiness WirePepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological
- 1y agoPEPGPepGen Announces Highest Mean Splicing Correction Reported in DM1 PatientsBusiness Wire– 53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing – – PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related
- 1y agoPEPGKuehn Law Encourages Investors of PepGen Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of PepGen Inc. (NASDAQ: PEPG) breached...
- 1y agoPEPGPepGen Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsBusiness Wire– Last patient dosed in 15 mg/kg cohort of FREEDOM-DM1; on track to report topline data from study in early Q4 2025 – – FREEDOM to conclude with the 15 mg/kg cohort based on splicing and safety data observed to date;
- 1y agoPEPGPepGen Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPGGlobeNewswireNEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ:PEPG). Shareholders who purchased shares of PEPG during the class period listed are
- 1y agoPEPGPEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLPPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. ("PepGen" or the "Company")...
- 1y agoPEPGSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoPEPGINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. ("PepGen" or the "Company")...
- 1y agoPEPGShareholders of PepGen Inc. Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPGGlobeNewswireNEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ:PEPG). Shareholders who purchased shares of PEPG during the class period listed are
- 1y agoPEPGSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. ("PepGen" or the "Company")...
- 1y agoPEPGINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PepGen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 1y agoPEPGPepGen Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPGGlobeNewswireNEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ:PEPG). Shareholders who purchased shares of PEPG during the class period listed are
- 1y agoPEPGPepGen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights - PEPGPR NewswireThe Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG). Shareholders who purchased shares of PEPG during the...
- 1y agoPEPGPEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLPPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. ("PepGen" or the "Company")...
- 1y agoPEPGPepGen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - PEPGPR NewswireThe Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG). Shareholders who purchased shares of PEPG during the...
- 1y agoPEPGSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoPEPGSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. ("PepGen" or the "Company")...
- 1y agoPEPGShareholders of PepGen Inc. Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPGGlobeNewswireNEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ:PEPG). Shareholders who purchased shares of PEPG during the class period listed are
- 1y agoPEPGPEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLPGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options If you suffered
- 1y agoPEPGPEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLPPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. ("PepGen" or the "Company")...
- 1y agoPEPGThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit – PEPGGlobeNewswireNEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ:PEPG). Shareholders who purchased shares of PEPG during the class period listed are
- 1y agoPEPGINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoPEPGInvestors in PepGen Inc. Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPGGlobeNewswireNEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ:PEPG). Shareholders who purchased shares of PEPG during the class period listed are
- 1y agoPEPGThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPGPR NewswireThe Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG). Shareholders who purchased shares of PEPG during the...
- 1y agoPEPGPepGen Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPGGlobeNewswireNEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ:PEPG). Shareholders who purchased shares of PEPG during the class period listed are
- 1y agoPEPGINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. ("PepGen" or the "Company")...